Founded in 2019 out of research at the Karolinska Institute, BOOST Pharma focuses on novel mesenchymal stem-cell treatments for rare skeletal pediatric diseases, with its lead candidate BT-101 targeting osteogenesis imperfecta. BT-101 is designed for prenatal or early-life administration so the cells migrate to bone, engraft, and reduce fracture frequency by addressing the underlying genetic defect. Pre-clinical mouse studies demonstrated increased calcium deposition, alkaline phosphatase activity, and ectopic bone formation, while a human proof-of-concept in four children with Type III and IV OI showed improved growth curves and markedly fewer fractures without safety issues or immune reactions. The company positions BT-101 as the first disease-modifying therapy for OI, aiming to enhance bone strength and potentially lung function throughout childhood. Current efforts are directed toward advancing BT-101 through clinical development and ultimately to market. Financially, BOOST Pharma has just secured an additional €3.1 million and is backed by a collaborative investor syndicate that now includes Sound Bioventures. The new funds extend the company’s runway to reach upcoming clinical milestones.

Total raised

$4M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2025